Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
18th April 2025
The New York Times, a Voice of the Crust.
A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.
The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.
Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. Industry analysts expect the drug to win approval sometime next year and to eventually become a major blockbuster. Eli Lilly is not expected to announce a price for the drug until after it wins approval.